The World Health Organization (WHO) has officially declared the Ebola outbreak in the Democratic Republic of the Congo (DRC) and Uganda a Public Health Emergency of International Concern (PHEIC), following reports of 516 suspected cases and 131 suspected deaths linked to the Bundibugyo strain of the virus.1
altona Diagnostics provides two solutions for the detection of the current Bundibugyo virus variant:
For detection: The RealStar® Filovirus Screen RT-PCR Kit 1.0, available as CE-IVD marked and as a RUO (research use only) version
For typing: The RealStar® Filovirus Type RT-PCR Kit 2.0, available as a RUO (research us only) version
Both altona Diagnostics kits are detecting the Bundibugyo virus as the following sources confirm:
A published evaluation of RealStar® reverse transcription-PCR kits for filovirus detection showed that the RealStar® filovirus screen kit detects all human-pathogenic filoviruses tested, including Ebola virus, Sudan virus, Tai Forest virus, Bundibugyo virus, Reston virus, and Marburg virus, with good analytical sensitivity when used on appropriate real-time PCR platforms.2
In addition, it was confirmed by an article that the RealStar® Filovirus Screen RT-PCR Kit 1.0 was used at Institut National de la Recherche Biomédicale (INRB) in Kinshasa (Democratic Republic of the Congo) in May 2026, and that it detected the currently circulating Bundibugyo virus variant in clinical samples.3 The article with the title “Initial genomes from May 2026 Bundibugyo Virus Disease Outbreak in the Democratic Republic of the Congo and Uganda” has been published by Placide Mbala. Mbala wrote: “On 14 May 2026, 13 samples (11 whole blood, 1 serum and 1 oro-pharyngeal swab) were tested at INRB, Kinshasa … using the Altona RealStar Filovirus Screen RT-PCR kit 1.0 (a pan Ebola- and Marburgvirus specific RNA detection kit). … Eight out of thirteen RNA samples were tested positive for Ebola virus by the used real-time PCR (Altona RealStar Filovirus Screen).”
altona Diagnostics is able to deliver its filovirus products into the DRC and Uganda. Either directly or under coordination by governmental or non-governmental organizations like WHO or ASLM (African Society for Laboratory Medicine). Furthermore, we have local African distributors who already ordered the altona products and can supply laboratories in their markets directly. All our shipments containing filovirus assays are export controlled.
Additional product shipments are being sent to several institutes for tropical medicine worldwide to ensure readiness for the rapidly evolving situation. Julia Narayanan, Head of Customer Care at altona Diagnostics, confirms: “Many organizations and partners have already reached out to us, and we are doing everything we can to support them in their response to the outbreak.”
altona Diagnostics is a medical diagnostic company that develops and manufactures in vitro diagnostic tests for the PCR based detection of pathogens such as viruses, bacteria, or parasites. Headquartered in Hamburg-Altona, Germany, altona Diagnostics is privately owned and employs more than 350 people worldwide, thereof 300 in Hamburg, Germany. The company has been in the molecular diagnostics business for over 25 years and is ISO 13485 certified. altona Diagnostics sells its registered products to medical laboratories globally through subsidiaries and more than 40 distribution partners.
Molecular diagnostic tests from altona Diagnostics are based on real-time PCR technology. altona Diagnostics offers the AltoStar® Molecular Diagnostic Workflow, an automated solution that is complete with instrumentation, reagents, consumables, and software. Furthermore, the company’s product catalog contains over 50 CE-IVD marked PCR tests that are also compatible with many open real-time PCR platforms.
For further information, please contact: | |
| Meike Thiel | Phone: +49 (0)40 5480676-0 |
| altona Diagnostics GmbH | Fax: +49 (0)40 5480676-10 |
| Mörkenstr. 12 | info@altona-diagnostics.com |
| 22767 Hamburg, Germany | www.altona-diagnostics.com |
For further information, please contact:
Meike Thiel
altona Diagnostics GmbH
Mörkenstr. 12
22767 Hamburg, Germany
Phone: +49 (0)40 5480676-0
Fax: +49 (0)40 5480676-10
Have a look at our news page for the Ebola Bundibugyo outbreak for detailed information and the latest updates on the outbreak situation, as well as on altona Diagnostics products for the detection of the current Bundibugyo virus variant.
Resources
1 WHO: Ebola Bundibugyo virus disease outbreak Democratic Republic of Congo | Uganda
https://iris.who.int/server/api/core/bitstreams/b6e1e783-91c3-43c8-ab90-16ceaa9948f0/content
2 Evaluation of RealStar Reverse Transcription–Polymerase Chain Reaction Kits for Filovirus Detection in the Laboratory and Field
https://pmc.ncbi.nlm.nih.gov/articles/PMC5050472/
3 Initial genomes from May 2026 Bundibugyo Virus Disease Outbreak in the Democratic Republic of the Congo and Uganda
Release date: 2026-05-21
Release date: 2026-05-21
You need to load content from reCAPTCHA to submit the form. Please note that doing so will share data with third-party providers.
More InformationYou are currently viewing a placeholder content from Turnstile. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More InformationYou are currently viewing a placeholder content from Vimeo. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More InformationYou are currently viewing a placeholder content from YouTube. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More InformationYou need to load content from reCAPTCHA to submit the form. Please note that doing so will share data with third-party providers.
More InformationYou are currently viewing a placeholder content from Facebook. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More InformationYou are currently viewing a placeholder content from Instagram. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More InformationYou are currently viewing a placeholder content from X. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More Information